Regeneron Pharmaceuticals Inc.has been in the news this year – first because of its successful launch of ophthalmology drug Eylea (aflibercept). More recently, clinical data is starting to come in for its antibody pipeline, notably with positive Phase II data on its cholesterol-lowering compound, which was the subject of a late-breaking session at the American College of Cardiology on March 26.
The drug, an antibody to proprotein convertase subtilisin/kexin type 9, is slated to enter Phase III clinical trials in the...